University of Leicester
Browse
Prevalence, risk factors and treatments for post-COVID-19 breathlessness.pdf (1.03 MB)

Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis

Download (1.03 MB)
journal contribution
posted on 2022-12-09, 16:36 authored by B Zheng, L Daines, Q Han, JR Hurst, P Pfeffer, M Shankar-Hari, O Elneima, S Walker, JS Brown, S Siddiqui, JK Quint, CE Brightling, RA Evans, LV Wain, LG Heaney, A Sheikh
Persistent breathlessness >28 days after acute COVID-19 infection has been identified as a highly debilitating post-COVID symptom. However, the prevalence, risk factors, mechanisms and treatments for post-COVID breathlessness remain poorly understood. We systematically searched PubMed and Embase for relevant studies published from 1 January 2020 to 1 November 2021 (PROSPERO registration number: CRD42021285733) and included 119 eligible papers. Random-effects meta-analysis of 42 872 patients with COVID-19 reported in 102 papers found an overall prevalence of post-COVID breathlessness of 26% (95% CI 23–29) when measuring the presence/absence of the symptom, and 41% (95% CI 34–48) when using Medical Research Council (MRC)/modified MRC dyspnoea scale. The pooled prevalence decreased significantly from 1–6 months to 7–12 months post-infection. Post-COVID breathlessness was more common in those with severe/critical acute infection, those who were hospitalised and females, and was less likely to be reported by patients in Asia than those in Europe or North America. Multiple pathophysiological mechanisms have been proposed (including deconditioning, restrictive/obstructive airflow limitation, systemic inflammation, impaired mental health), but the body of evidence remains inconclusive. Seven cohort studies and one randomised controlled trial suggested rehabilitation exercises may reduce post-COVID breathlessness. There is an urgent need for mechanistic research and development of interventions for the prevention and treatment of post-COVID breathlessness.

Funding

This study was supported by a grant to the University of Leicester from the MRC–UK Research and Innovation (UKRI) and the Department of Health and Social Care (DHSC) through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19 (grants: MR/V027859/1 and COV0319). The study was also supported by the UK Health Data Research BREATHE Hub and the Chief Scientist Office of the Scottish Government (COV/LTE/20/15).

History

Citation

Zheng B, Daines L, Han Q, et al. Prevalence, risk factors and treatments for postCOVID-19 breathlessness: a systematic review and meta-analysis. Eur Respir Rev 2022; 31: 220071 [DOI: 10.1183/16000617.0071-2022].

Author affiliation

Institute for Lung Health, Leicester NIHR Biomedical Research Centre; Dept of Respiratory Sciences; Dept of Health Sciences

Version

  • VoR (Version of Record)

Published in

European Respiratory Review

Volume

31

Issue

166

Pagination

220071

Publisher

European Respiratory Society (ERS)

issn

0905-9180

eissn

1600-0617

Acceptance date

2022-07-04

Copyright date

2022

Available date

2022-12-09

Language

eng

Usage metrics

    University of Leicester Publications

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC